89 related articles for article (PubMed ID: 8230254)
1. Bryostatin 1: will the oceans provide a cancer cure?
Kraft AS
J Natl Cancer Inst; 1993 Nov; 85(22):1790-2. PubMed ID: 8230254
[No Abstract] [Full Text] [Related]
2. Clinical trials referral resource. Clinical trials using bryostatin-1.
Pluda JM; Cheson BD; Phillips PH
Oncology (Williston Park); 1996 May; 10(5):740-2. PubMed ID: 8738829
[No Abstract] [Full Text] [Related]
3. The clinical development of the bryostatins.
Clamp A; Jayson GC
Anticancer Drugs; 2002 Aug; 13(7):673-83. PubMed ID: 12187323
[TBL] [Abstract][Full Text] [Related]
4. Bryostatin-I: an antineoplastic treasure from the deep?
May WS; Ruvolo PP
Cancer Biol Ther; 2002; 1(4):417-9. PubMed ID: 12432258
[No Abstract] [Full Text] [Related]
5. Cytotoxic Bryostatin Derivatives from the South China Sea Bryozoan Bugula neritina.
Yu HB; Yang F; Li YY; Gan JH; Jiao WH; Lin HW
J Nat Prod; 2015 May; 78(5):1169-73. PubMed ID: 25932671
[TBL] [Abstract][Full Text] [Related]
6. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
7. The bryostatins.
Pettit GR
Fortschr Chem Org Naturst; 1991; 57():153-195. PubMed ID: 1937312
[No Abstract] [Full Text] [Related]
8. Bryostatin 1: differentiating agent from the depths.
Stone RM
Leuk Res; 1997 May; 21(5):399-401. PubMed ID: 9225066
[No Abstract] [Full Text] [Related]
9. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
Philip PA; Rea D; Thavasu P; Carmichael J; Stuart NS; Rockett H; Talbot DC; Ganesan T; Pettit GR; Balkwill F
J Natl Cancer Inst; 1993 Nov; 85(22):1812-8. PubMed ID: 8230261
[TBL] [Abstract][Full Text] [Related]
10. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.
Varterasian ML; Pemberton PA; Hulburd K; Rodriguez DH; Murgo A; Al-Katib AM
Invest New Drugs; 2001; 19(3):245-7. PubMed ID: 11561682
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of murine melanoma with bryostatin 1.
Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
[TBL] [Abstract][Full Text] [Related]
13. Potential for protein kinase C inhibitors in cancer therapy.
Philip PA; Harris AL
Cancer Treat Res; 1995; 78():3-27. PubMed ID: 8595146
[No Abstract] [Full Text] [Related]
14. Chemistry and clinical biology of the bryostatins.
Mutter R; Wills M
Bioorg Med Chem; 2000 Aug; 8(8):1841-60. PubMed ID: 11003129
[TBL] [Abstract][Full Text] [Related]
15. Laboratory and phase I studies of new cancer drugs.
Workman P; Kaye SB; Schwartsmann G
Curr Opin Oncol; 1992 Dec; 4(6):1065-72. PubMed ID: 1360819
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
Hornung RL; Pearson JW; Beckwith M; Longo DL
Cancer Res; 1992 Jan; 52(1):101-7. PubMed ID: 1727368
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
[TBL] [Abstract][Full Text] [Related]
18. Marine organisms as a source of new anticancer agents.
Schwartsmann G; Brondani da Rocha A; Berlinck RG; Jimeno J
Lancet Oncol; 2001 Apr; 2(4):221-5. PubMed ID: 11905767
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic agents, 118. Isolation and structure of bryostatin 9.
Pettit GR; Kamano Y; Herald CL
J Nat Prod; 1986; 49(4):661-4. PubMed ID: 3783162
[No Abstract] [Full Text] [Related]
20. The chemistry and biology of the bryostatin antitumour macrolides.
Hale KJ; Hummersone MG; Manaviazar S; Frigerio M
Nat Prod Rep; 2002 Aug; 19(4):413-53. PubMed ID: 12195811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
